2-({[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methyl}amino)-5-cyano-N-[(1S)-1-(3,4-difluorophenyl)ethyl]pyridine-3-carboxamide | 1289187-06-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-({[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methyl}amino)-5-cyano-N-[(1S)-1-(3,4-difluorophenyl)ethyl]pyridine-3-carboxamide
• 英文别名: US10030016, Example 8.8.2；2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-5-cyano-N-[(1S)-1-(3,4-difluorophenyl)ethyl]pyridine-3-carboxamide
• CAS: 1289187-06-9
• 化学式: C₂₈H₂₁F₂N₇OS
• 分子量: 541.584
• InChiKey: BSVLRYRPCKCJGU-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  39
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  158
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS
  申请人：Arndt Joseph

  公开号：US20120208819A1

  公开（公告）日：2012-08-16

  The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

  本发明提供了作为PDK1抑制剂有用的化合物。本发明还提供了它们的组合物，以及治疗PDK1介导的疾病的方法。
• HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER
  申请人：Sunesis Pharmaceuticals, Inc.

  公开号：EP3763368A1

  公开（公告）日：2021-01-13

  Described are methods of use of compounds that inhibit PIF-mediated substrate binding by PDK1, which are useful as inhibitors of cancer growth or proliferation that is RSK2-dependent or AKT-independent. Also described are compositions of such compounds for use in such methods of treating cancer.

  描述了抑制 PIF 介导的底物与 PDK1 结合的化合物的使用方法，这些化合物可用作 RSK2 依赖性或 AKT 非依赖性癌症生长或增殖的抑制剂。还描述了用于此类治疗癌症方法的此类化合物的组合物。
• Heterocyclic compounds useful as PDK1 inhibitors
  申请人：Sunesis Pharmaceuticals, Inc.

  公开号：US10030016B2

  公开（公告）日：2018-07-24

  The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

  本发明提供了可用作 PDK1 抑制剂的化合物。 本发明还提供了其组合物以及治疗 PDK1 介导的疾病的方法。
• US9546165B2
  申请人：——

  公开号：US9546165B2

  公开（公告）日：2017-01-17
• [EN] HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER<br/>[FR] INHIBITEURS DE PDK1 HÉTÉROCYCLIQUES DESTINÉS À ÊTRE UTILISÉS POUR TRAITER LE CANCER
  申请人：SUNESIS PHARMACEUTICALS INC

  公开号：WO2017070565A1

  公开（公告）日：2017-04-27

  Described are methods of use of compounds that inhibit PIF-mediated substrate binding by PDK1, which are useful as inhibitors of cancer growth or proliferation that is RSK2-dependent or AKT-independent. Also described are compositions of such compounds for use in such methods of treating cancer.